Koru Medical Systems, INC 8-K filings

KORU Medical Systems, Inc. has amended its manufacturing and supply agreement with Command Medical Products, LLC, extending the term, modifying pricing, and establishing a second manufacturing site.

KORU Medical Systems, Inc. reported voting results from its 2026 Annual Meeting of Shareholders, with all director nominees elected and key proposals approved.

KORU Medical Systems reported a 22% increase in first-quarter net revenues to $11.8 million, driven by core business growth and international expansion, while also reiterating full-year 2026 financial guidance.

KORU Medical Systems, Inc. has amended its loan and security agreement with HSBC Ventures USA Inc., extending credit facility maturities and adjusting covenants.

KORU Medical Systems announces CEO Linda Tharby's retirement and the appointment of Adam Kalbermatten as her successor, effective July 1, 2026, with a structured transition plan.

KORU Medical Systems announced robust fourth quarter and full year 2025 financial results, achieving significant revenue growth and positive adjusted EBITDA, while initiating optimistic 2026 guidance.

KORU Medical Systems announced preliminary unaudited results for Q4 and full year 2025, reporting record revenue and positive operating cash flow.

KORU Medical Systems, Inc. has entered into an amended and restated manufacturing and supply agreement with Command Medical Products, LLC, effective January 1, 2024, securing continued supply of critical medical device components.

KORU Medical Systems reported strong third-quarter 2025 financial results, including a 27% revenue increase and raised full-year revenue guidance.

KORU Medical Systems reported record Q2 2025 net revenues of $10.2 million, a 21% increase year-over-year, and raised its full-year 2025 revenue guidance.

KORU Medical Systems reports the outcomes of its 2025 Annual Meeting of Shareholders, including the election of directors, approval of executive compensation, and ratification of independent accountants.

KORU Medical Systems reports strong Q1 2025 results with an 18% revenue increase and raises its full-year revenue guidance.

KORU Medical Systems announces the resignation of its Chief Commercial Officer, Kenneth Miller, effective immediately, and reaffirms its full-year 2025 revenue guidance of $38.0-$39.0 million.

KORU Medical Systems extends its loan agreement with HSBC Ventures, pushing out maturity dates and modifying financial covenants to enhance financial flexibility.

KORU Medical Systems announces strong financial results for Q4 and full year 2024, with record revenues and gross profit, and issues optimistic guidance for 2025, including expectations for positive operational cash flow.

KORU Medical Systems reports record full-year and quarterly revenues, along with positive cash flow for the fourth quarter of 2024.

KORU Medical Systems announced a 17% increase in third-quarter revenue, driven by double-digit growth and raised its full-year 2024 guidance for revenue, gross margin, and year-end cash balance.

KORU Medical Systems has approved a new Long-Term Incentive Program (LTIP) and granted equity-based awards to its executive officers and other employees.

KORU Medical Systems announced a record second quarter with 22% revenue growth and raised its full-year 2024 revenue and gross margin guidance.

KORU Medical Systems has appointed Christopher Pazdan as its new Chief Operating Officer, while also eliminating the Chief Technology Officer position.

KORU Medical Systems has dismissed McGrail Merkel Quinn & Associates, P.C. and engaged Cherry Bekaert LLP as its new independent registered public accounting firm, effective immediately on June 3, 2024.

Koru Medical Systems held its 2024 Annual Meeting of Shareholders on May 9, 2024, where all director nominees were elected and key proposals were approved.

KORU Medical Systems announced a strong start to 2024 with an 11% increase in first-quarter revenue and a new oncology collaboration.

KORU Medical Systems has successfully appealed a negative assessment report from its EU notified body, BSI, allowing the company to continue selling its products in the European Union without interruption.

KORU Medical announced a new $10 million credit facility, alongside its fourth quarter and full year 2023 financial results, and provided revenue guidance for 2024.